Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression

Eduardo M. Sotomayor, Ivan M Borrello, Frédérique Marie Rattis, Alex G. Cuenca, Jacob Abrams, Kevin Staveley-O'Carroll, Hyam I. Levitsky

Research output: Contribution to journalArticle

Abstract

Tumor antigen-specific T-cell tolerance may limit the efficacy of therapeutic cancer vaccines. Direct presentation of antigens by tumor cells incapable of providing adequate costimulation to tumor-specific T cells has been suggested as the basis for this unresponsiveness. Using parent-into-F1 bone marrow (BM) chimeras, this study unambiguously demonstrates that the induction of this tolerant state requires T-cell recognition of tumor antigen presented by BM-derived antigen-presenting cells (APCs), not tumor cells themselves. In the absence of host APC presentation, tumor-specific T cells remained functional, even in the setting of antigen expressed by B-cell lymphomas residing in secondary lymphoid tissues. The intrinsic APC capacity of tumor cells has therefore little influence over T-cell priming versus tolerance, a decision that is regulated at the level of host APCs.

Original languageEnglish (US)
Pages (from-to)1070-1077
Number of pages8
JournalBlood
Volume98
Issue number4
DOIs
StatePublished - Aug 15 2001

Fingerprint

Cross-Priming
T-cells
B-Cell Lymphoma
Neoplasm Antigens
Antigen-Presenting Cells
Bone
Bone Marrow
Cells
Tumors
T-Lymphocytes
Neoplasms
Cancer Vaccines
Antigen Presentation
Lymphoid Tissue
Tissue
Antigens

ASJC Scopus subject areas

  • Hematology

Cite this

Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression. / Sotomayor, Eduardo M.; Borrello, Ivan M; Rattis, Frédérique Marie; Cuenca, Alex G.; Abrams, Jacob; Staveley-O'Carroll, Kevin; Levitsky, Hyam I.

In: Blood, Vol. 98, No. 4, 15.08.2001, p. 1070-1077.

Research output: Contribution to journalArticle

Sotomayor, Eduardo M. ; Borrello, Ivan M ; Rattis, Frédérique Marie ; Cuenca, Alex G. ; Abrams, Jacob ; Staveley-O'Carroll, Kevin ; Levitsky, Hyam I. / Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression. In: Blood. 2001 ; Vol. 98, No. 4. pp. 1070-1077.
@article{8ac48fb678ea4f6c97943aaf5304d7e4,
title = "Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression",
abstract = "Tumor antigen-specific T-cell tolerance may limit the efficacy of therapeutic cancer vaccines. Direct presentation of antigens by tumor cells incapable of providing adequate costimulation to tumor-specific T cells has been suggested as the basis for this unresponsiveness. Using parent-into-F1 bone marrow (BM) chimeras, this study unambiguously demonstrates that the induction of this tolerant state requires T-cell recognition of tumor antigen presented by BM-derived antigen-presenting cells (APCs), not tumor cells themselves. In the absence of host APC presentation, tumor-specific T cells remained functional, even in the setting of antigen expressed by B-cell lymphomas residing in secondary lymphoid tissues. The intrinsic APC capacity of tumor cells has therefore little influence over T-cell priming versus tolerance, a decision that is regulated at the level of host APCs.",
author = "Sotomayor, {Eduardo M.} and Borrello, {Ivan M} and Rattis, {Fr{\'e}d{\'e}rique Marie} and Cuenca, {Alex G.} and Jacob Abrams and Kevin Staveley-O'Carroll and Levitsky, {Hyam I.}",
year = "2001",
month = "8",
day = "15",
doi = "10.1182/blood.V98.4.1070",
language = "English (US)",
volume = "98",
pages = "1070--1077",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "4",

}

TY - JOUR

T1 - Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression

AU - Sotomayor, Eduardo M.

AU - Borrello, Ivan M

AU - Rattis, Frédérique Marie

AU - Cuenca, Alex G.

AU - Abrams, Jacob

AU - Staveley-O'Carroll, Kevin

AU - Levitsky, Hyam I.

PY - 2001/8/15

Y1 - 2001/8/15

N2 - Tumor antigen-specific T-cell tolerance may limit the efficacy of therapeutic cancer vaccines. Direct presentation of antigens by tumor cells incapable of providing adequate costimulation to tumor-specific T cells has been suggested as the basis for this unresponsiveness. Using parent-into-F1 bone marrow (BM) chimeras, this study unambiguously demonstrates that the induction of this tolerant state requires T-cell recognition of tumor antigen presented by BM-derived antigen-presenting cells (APCs), not tumor cells themselves. In the absence of host APC presentation, tumor-specific T cells remained functional, even in the setting of antigen expressed by B-cell lymphomas residing in secondary lymphoid tissues. The intrinsic APC capacity of tumor cells has therefore little influence over T-cell priming versus tolerance, a decision that is regulated at the level of host APCs.

AB - Tumor antigen-specific T-cell tolerance may limit the efficacy of therapeutic cancer vaccines. Direct presentation of antigens by tumor cells incapable of providing adequate costimulation to tumor-specific T cells has been suggested as the basis for this unresponsiveness. Using parent-into-F1 bone marrow (BM) chimeras, this study unambiguously demonstrates that the induction of this tolerant state requires T-cell recognition of tumor antigen presented by BM-derived antigen-presenting cells (APCs), not tumor cells themselves. In the absence of host APC presentation, tumor-specific T cells remained functional, even in the setting of antigen expressed by B-cell lymphomas residing in secondary lymphoid tissues. The intrinsic APC capacity of tumor cells has therefore little influence over T-cell priming versus tolerance, a decision that is regulated at the level of host APCs.

UR - http://www.scopus.com/inward/record.url?scp=0035883073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035883073&partnerID=8YFLogxK

U2 - 10.1182/blood.V98.4.1070

DO - 10.1182/blood.V98.4.1070

M3 - Article

VL - 98

SP - 1070

EP - 1077

JO - Blood

JF - Blood

SN - 0006-4971

IS - 4

ER -